Sorrento Therapeutics, Inc. (SRNE): Price and Financial Metrics

Sorrento Therapeutics, Inc. (SRNE)

Today's Latest Price: $4.12 USD

0.26 (6.74%)

Updated Jun 5 4:00pm

Add SRNE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

SRNE Stock Summary

  • With a price/sales ratio of 26.17, Sorrento Therapeutics Inc has a higher such ratio than 94.48% of stocks in our set.
  • Revenue growth over the past 12 months for Sorrento Therapeutics Inc comes in at 56.52%, a number that bests 90.86% of the US stocks we're tracking.
  • The volatility of Sorrento Therapeutics Inc's share price is greater than that of 88.5% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to SRNE, based on their financial statements, market capitalization, and price volatility, are VERU, IOTS, KPTI, NWBO, and RDUS.
  • Visit SRNE's SEC page to see the company's official filings. To visit the company's web site, go to
SRNE Daily Price Range
SRNE 52-Week Price Range

SRNE Stock Price Chart More Charts

SRNE Price/Volume Stats

Current price $4.12 52-week high $10.00
Prev. close $3.86 52-week low $1.39
Day low $4.00 Volume 33,729,243
Day high $4.56 Avg. volume 17,979,195
50-day MA $3.22 Dividend yield N/A
200-day MA $2.73 Market Cap 863.92M

Sorrento Therapeutics, Inc. (SRNE) Company Bio

Sorrento Therapeutics is a clinical stage oncology company developing new treatments for cancer and associated pain. The company was founded in 2006 and is based in San Diego, California.

SRNE Latest News Stream

Event/TimeNews Detail
Loading, please wait...

SRNE Latest Social Stream

Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Sorrento up 15% on encouraging COVIDTRAP data

Sorrento Therapeutics ([[SRNE]] +14.6%) is up in early trade on the heels of its announcement of positive preclinical data on STI-4398 ((COVIDTRAP)).STI-4398, an ACE2 (angiotensin-converting enzyme 2)-Fc fusion protein, binds to the SARS-CoV-2 spike protein. Results from an in vitro assay showed that it "completely inhibited" the ability of the...

Seeking Alpha | June 5, 2020

Sorrento Reports It Has a Second Potential Antidote for COVID-19

On Friday, Sorrento Therapeutics (NASDAQ: SRNE) announced positive results from preclinical testing of STI-4398, a protein to neutralize the SARS-CoV-2 virus. The company said that the drug candidate it has nicknamed "Covidtrap" completely inhibited the ability of the coronavirus to infect cells that have the same ACE2 receptors that are present on the respiratory epithelial cells that it targets in humans. The company has discussed the drug with the Food and Drug Administration and has received guidance for advancing it both as a treatment for patients infected with the virus and as a prophylactic measure for preventing COVID-19.

Yahoo | June 5, 2020

SHAREHOLDER ALERT: CTMX SRNE CLNY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / June 5, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, ...

Yahoo | June 5, 2020

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 4, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Sorrento Therapeutics, Inc. ("Sorrento" or "the Company") (NASDAQ:SRNE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 15, 2020 and May 22, 2020, inclusive (the ''Class Period'') are encouraged to contact the firm before July 27, 2020.

Yahoo | June 5, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sorrento Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 27, 2020 - SRNE

New York, New York--(Newsfile Corp. - June 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento") between May 15, 2020 and May 20, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of California. To ...

Yahoo | June 5, 2020

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo 70.95%
3-mo 86.43%
6-mo 8.14%
1-year 39.66%
3-year 157.50%
5-year -72.59%
YTD 21.89%
2019 40.83%
2018 -36.84%
2017 -22.45%
2016 -43.74%
2015 -13.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7567 seconds.